ANN ARBOR, Mich., Sept. 16, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that Ronnda Bartel, PhD, the company’s chief scientific officer, will be a featured presenter at the Cell Therapy Commercialization Summit to be held September 19-21, 2011, in Boston, Massachusetts. Dr. Bartel will present an overview of ixmyelocel-T, the company’s patient-specific, expanded multicellular therapy currently in Phase 3 development for the treatment of critical limb ischemia and in Phase 2 clinical trials for the treatment of dilated cardiomyopathy.
